Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius AGSARTF 85 Cash-to-Debt is 0.08 as of Jun. 2026, which is 33% below its 10-year median of 0.12. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $231.88 (Fairly Valued). The stock has 6 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Sartorius AG ranks worse than 92.56% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sartorius AG's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.08.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Sartorius AGcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Sartorius AG's Cash-to-Debt or its related term are showing as below:
SARTF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 0.12 Max: 0.25
Current: 0.08
During the past 13 years, Sartorius AG's highest Cash to Debt Ratio was 0.25. The lowest was 0.05. And the median was 0.12.
SARTF's Cash-to-Debt is ranked worse than 92.56% of 847
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs SARTF: 0.08
Sartorius AG (OTCPK:SARTF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Sartorius AG Cash-to-Debt Related Terms
Sartorius AG Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Sartorius AG's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, Sartorius AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sartorius AG's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a Cash-to-Debt of 0.08 as of Jun. 2026. This is 33% below median its historical median of 0.12. Over the past decade, Sartorius AG's Cash-to-Debt has ranged from 0.05 to 0.25. According to the industry distribution chart, Sartorius AG ranks #784 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 92.6%.
Is Sartorius AG's Cash-to-Debt too high?
Sartorius AG's current Cash-to-Debt of 0.08 is 33% below median its 10-year median of 0.12. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.25. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. Sartorius AG's value of 0.08 is 95.2% below this industry median. Based on the distribution chart, Sartorius AG ranks #784 out of 847 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #784 out of 847 companies for Cash-to-Debt. This places Sartorius AG in the lower half of its industry. The industry median Cash-to-Debt is 1.68. Sartorius AG's value of 0.08 is 95.2% below this benchmark. Historically, Sartorius AG's own Cash-to-Debt has ranged from 0.05 to 0.25 over the past decade. While the company's 10-year median is 0.12 vs. the industry median of 1.68, Sartorius AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current Cash-to-Debt of 0.08 is 95.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current Cash-to-Debt is 0.08, which is 33% below median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Fairly Valued. The stock's GF Value™ is $231.88, compared to a current price of $212.80 — trading 8.2% below its estimated fair value. The current Cash-to-Debt is 0.08, which is 33% below median its 10-year median of 0.12 and 95.2% below the Medical Devices & Instruments industry median of 1.68. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Cash-to-Debt is 0.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 8.2% below its estimated GF Value™ of $231.88.
GuruFocus considers Sartorius AG to be Fairly Valued.
Key valuation signals for SARTF:
Cash-to-Debt: 0.08 (33% below median its 10-year median of 0.12)
GF Value™: $231.88 vs. price of $212.80 (8.2% below fair value)
Industry Position: 95.2% below the Medical Devices & Instruments median (#784 of 847)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
